Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Viking Therapeutics, Inc. (VKTX)

Add VKTX Price Alert      Hide Sticky   Hide Intro
Moderator: greens12, BrazenBull
Search This Board: 
Last Post: 11/17/2017 5:34:30 PM - Followers: 33 - Board type: Free - Posts Today: 0

Novel therapeutics for metabolic<Br/>and endocrine disorders
  1. 2


Viking Therapeutics is focused on the development of novel therapeutics for patients suffering from metabolic and endocrine disorders.

Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of patients recovering from non-elective hip fracture surgery. The Company’s second program is focused on the development of first-in-class, selective, small molecule agonists of the thyroid receptor beta, or TRß, for adrenoleukodystrophy, or ALD, and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis, or NASH. Viking is also developing additional programs targeted at diabetes, metabolic diseases and anemia.



We have a portfolio of five drug candidates in clinical trials or preclinical studies

Our lead clinical program, VK5211, is a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 is designed to produce the therapeutic benefits of testosterone in muscle and bone with improved safety, tolerability and patient acceptance. We have initiated a Phase 2 clinical trial with VK5211 in patients recovering from non-elective hip fracture surgery. For more information on this study please visit NCT02578095.

Our second pipeline program is focused on the development of novel small molecule agonists of the thyroid beta (TRb) receptor, VK2809 and VK0214. These novel TRb agonists are being developed for hypercholesterolemia and fatty liver disease and X-linked adrenoleukodystrophy, or X-ALD. We have initiated Phase 2 clinical development of VK 2809 in hypercholesterolemia and fatty liver disease. VK0214 is in preclinical development for X-ALD.

We are also developing VK0612, a first-in-class, orally available drug 

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VKTX News: Quarterly Report (10-q) 11/08/2017 05:12:26 PM
VKTX News: Current Report Filing (8-k) 11/08/2017 04:13:01 PM
VKTX News: Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 11/08/2017 04:05:00 PM
VKTX News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 10/26/2017 04:54:21 PM
VKTX News: Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at... 10/24/2017 07:05:00 AM
#1044   You can’t build muscle from nothin. Body ZeWaffleBaron 11/17/17 05:34:30 PM
#1043   VK-5211 Lean Body Mass [LBM] hptaxis 11/17/17 04:52:09 PM
#1042   Hey buddy. I knew I liked u ZeWaffleBaron 11/17/17 12:51:42 PM
#1041   Another Green Day,looks like it wants to go greens12 11/16/17 10:48:01 AM
#1040   Right on brother!! I actually worked directly in BrazenBull 11/16/17 04:57:11 AM
#1039   Right there with ya brother. Gave me ZeWaffleBaron 11/15/17 08:39:09 PM
#1038   Wow, I am getting a little stir BrazenBull 11/15/17 02:45:35 AM
#1037   Agreed, vk5211 Data will be good and this greens12 11/11/17 09:30:33 PM
#1036   Pretty sure results in hand and they are zoomlik 11/10/17 04:17:26 PM
#1035   I think they will meet Primary and will be zoomlik 11/10/17 02:00:02 PM
#1034   Thanks greens. I didn’t know p1 was done Titan V 11/10/17 11:15:00 AM
#1033   I think hptaxis May be correct .. but zoomlik 11/10/17 11:12:20 AM
#1032   "But its extensive clinical history may also shine greens12 11/09/17 10:09:59 PM
#1031   Viking Therapeutics: FY'17 Q3 Quarterly Update greens12 11/09/17 10:01:34 PM
#1030   Academic/clinical. Lol. The ihub stock message ZeWaffleBaron 11/09/17 07:30:09 PM
#1029   if he's short, more fuel for the fire greens12 11/09/17 05:25:07 PM
#1028   Did you really just compare VK5211 to enclomiphene? Lynx7 11/09/17 04:42:35 PM
#1027   Glad you have no holdings in vrtx Lynx7 11/09/17 04:40:19 PM
#1023   I have no holdings in VRTX, none. My hptaxis 11/09/17 01:36:52 PM
#1022   Are you short here now? zoomlik 11/09/17 11:25:41 AM
#1021  Restored In 2 years, CEO has milked this company hptaxis 11/09/17 09:43:11 AM
#1017   Ridiculous comment when the CEO has all his Rolling inflaton 11/08/17 05:50:05 PM
#1016  Restored Don't Bogart That joint ... hptaxis 11/08/17 05:42:44 PM
#1015   Well at least no bad new before earnings zoomlik 11/08/17 05:01:18 PM
#1014   Q3: net loss of $16.5 million, or $0.67 Wildbilly 11/08/17 04:22:23 PM
#1013   Hey buddy, Im a bit pessimistic in my ZeWaffleBaron 11/08/17 12:42:05 PM
#1012   still holding , just having a hard time greens12 11/08/17 11:29:43 AM
#1011   At least vol. says it wasn't a leak, Wildbilly 11/08/17 11:23:38 AM
#1009   Not looking good. Wildbilly 11/08/17 10:18:17 AM
#1008   Waffles, what would you realistically put our chances BrazenBull 11/08/17 02:23:58 AM
#1007   I agree it will go up strong after greens12 11/07/17 09:39:14 PM
#1006   There is still worry in vk5211 .. it zoomlik 11/07/17 03:34:51 PM
#1005   Are you saying they won't see whole body ZeWaffleBaron 11/06/17 04:24:45 PM
#1004   You are stating that participants will develop metabolic ZeWaffleBaron 11/06/17 04:22:12 PM
#1003   It means as if today, they don’t have zoomlik 11/06/17 12:39:20 PM
#1002   PPS seems to be confirming, nice little spurt. Wildbilly 11/06/17 12:35:55 PM
#1001   Thanks .. meant to ask it from hptaxis .. zoomlik 11/06/17 12:27:59 PM
#1000   This is actually very good news .. they zoomlik 11/06/17 12:19:00 PM
#999   Absolutely, The Valuation needs to catch up greens12 11/06/17 12:17:30 PM
#998   If they have unblinded data and are participating Titan V 11/06/17 12:16:55 PM
#997   Viking Therapeutics to Participate in Ligand Pharmaceuticals Analyst Titan V 11/06/17 12:10:38 PM
#996   Hptaxis I think you are right .. but do zoomlik 11/06/17 12:09:19 PM
#995   I think you are right .. but do zoomlik 11/06/17 12:07:39 PM
#994 this very carefully..."Hormone levels and lipids returned greens12 11/06/17 11:17:09 AM
#993   Further, hypogonadism post cessation will lead to a hptaxis 11/06/17 11:13:40 AM
#992   Results. LGD-4033 was well tolerated. There were no greens12 11/06/17 11:13:22 AM
#991   Hormone levels and lipids returned to baseline after greens12 11/06/17 11:12:53 AM
#990   HDL ... 2 mg dose will have an hptaxis 11/06/17 11:04:52 AM
#989   Phase 1 was a Mice study, Its not greens12 11/06/17 11:04:28 AM
#988   Also why wasn’t this an issue on the Titan V 11/06/17 10:54:08 AM